文献速递前列腺癌

根治性治疗后生化复发且前列腺特异性抗原倍增时间短患者的真实世界结局:早期二级治疗的潜在作用

Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-09-13

快速PSADT与更短的首次全身抗肿瘤治疗时间、转移时间、转移无生存期和总生存期相关。多数快速PSADT患者在生化复发后1年内接受了二级治疗,早期二级治疗患者的结局优于历史延迟治疗数据,但获益来源需进一步研究。

要点

  • PSADT≤9个月组首次全身治疗中位时间11.4个月,较>9至≤15个月组28.3个月更短。
  • 快速PSADT组转移风险比为1.79,转移无生存期和总生存期均更短。
  • 多数快速PSADT患者在生化复发后1年内接受二级治疗,结局优于历史延迟治疗数据。

核心结论

  • 多数快速PSADT患者在生化复发后1年内接受了二级治疗。
  • 接受早期二级治疗的当代患者结局优于历史延迟治疗数据。
  • 这些结果反映早期二级治疗获益还是前列腺癌结局总体改善需进一步研究。

研究设计与样本

  • 纳入781例非转移性去势敏感性前列腺癌生化复发患者,分为快速PSADT组(≤9个月,502例)和较慢PSADT组(>9至≤15个月,279例)。
  • PSADT>15个月患者被排除;采用Cox模型校正基线人口学和临床特征。

主要发现

  • 快速PSADT组较慢速PSADT组首次全身抗肿瘤治疗中位时间更短(11.4 vs 28.3个月,校正HR 2.17,95%CI 1.83-2.57)。
  • 快速PSADT组转移时间更短(中位102.4个月 vs 未达到,HR 1.79,95%CI 1.33-2.40)。
  • 快速PSADT组转移无生存期更短(76.1 vs 106.3个月,HR 1.73,95%CI 1.33-2.24)。
  • 快速PSADT组总生存期更短(120.5 vs 140.5个月,HR 1.76,95%CI 1.22-2.54)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出,这些结果反映早期二级治疗获益还是前列腺癌结局总体改善需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The natural history of biochemical recurrence (BCR) managed with delayed hormonal therapy is well documented by data from Johns Hopkins. However, as many patients receive treatment prior to metastasis, we evaluated the natural history and role of prostate-specific antigen doubling time (PSADT) in a more contemporary cohort of BCR patients with nonmetastatic castration-sensitive prostate cancer (nmCSPC). METHODS: Patients in the Veterans Health Administration (VHA; 01/01/06 to 06/22/20) with nmCSPC and BCR were divided into rapid ( ≤9 months) and less rapid ( >9 to ≤15 months) PSADT cohorts. Patients with PSADT >15 months were excluded as outcomes, even with delayed treatment, are excellent. Outcomes included time to first antineoplastic therapy after BCR, metastasis, metastasis-free survival (MFS), and overall survival (OS). Cox models adjusted for baseline demographics and clinical characteristics. RESULTS: Overall, 781 patients with BCR were identified (502 rapid; 279 less rapid PSADT). Rapid PSADT was associated with shorter time to first systemic antineoplastic therapy (median 11.4 vs. 28.3 months, adjusted hazard ratio [95% confidence interval] 2.17 [1.83-2.57]), metastasis (102.4 months vs. not reached, 1.79 [1.33-2.40]), MFS (76.1 vs. 106.3 months, 1.73 [1.33-2.24]), and OS (120.5 vs. 140.5 months, 1.76 [1.22-2.54]) versus less rapid PSADT. CONCLUSION: Most patients with rapid PSADT underwent secondary treatment within 1 year after BCR. More contemporary patients treated with early secondary treatment had better outcomes than historical data from patients who had delayed treatment. Whether these results reflect the benefits of early secondary treatment or overall improvements in prostate cancer outcomes over time requires further study.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Freedland SJ, Gao W, Lax A, et al. Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment. Prostate Cancer Prostatic Dis. 2024. PMID: 39271770. doi:10.1038/s41391-024-00894-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。